Clinical Edge Journal Scan

Attention deficit hyperactivity disorder increases the risk for migraine in children and adolescents


 

Key clinical point: The prevalence of migraine is higher in children and adolescents with attention deficit hyperactivity disorder (ADHD) vs those without.

Major finding: The risk of developing migraine was significantly higher in patients with ADHD than in matched controls (adjusted hazard ratio [aHR] 1.92; 95% CI 1.64-2.31) with the risk being prominent in children (aHR 2.01; 95% CI 1.63-2.49) and adolescents (aHR 1.94; 95% CI 1.35-2.79) but not in young adults with ADHD.

Study details: This was a nationwide longitudinal case-cohort study including 81,441 patients (including children, adolescents, and young adults aged 3-11, 12-17, and 18-29 years, respectively) with ADHD and 81,441 matched controls without ADHD.

Disclosures: The study was supported by grants from Taipei Veterans General Hospital; Kaohsiung Veterans General Hospital; Yen Tjing Ling Medical Foundation; and the Ministry of Science and Technology, Taiwan. The authors declared no conflicts of interest.

Source: Hsu T-W et al. Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study. Headache. 2022 (May 6). Doi: 10.1111/head.14306

Recommended Reading

Safety Concerns with CGRP Monoclonal Antibodies
Migraine ICYMI
Fremanezumab can prevent migraine across a broad real-world patient population
Migraine ICYMI
Evidence of real-world effectiveness of erenumab against chronic migraine
Migraine ICYMI
Migraine: Suboptimal first-dose responders may benefit from a second dose of eptinezumab
Migraine ICYMI
Galcanezumab reduces acute headache medication use in treatment-resistant migraine
Migraine ICYMI
Migraine: Ubrogepant therapy yields favorable 2-hour outcomes in triptan insufficient responders
Migraine ICYMI
Subcutaneous injection of diclofenac sodium is effective against acute migraine
Migraine ICYMI
Is migraine related to adverse pregnancy outcomes?
Migraine ICYMI
Patients with migraine show high adherence and persistence to fremanezumab in a real-world setting
Migraine ICYMI
Plasma glutamate level: A potential indicator for episodic and chronic migraines
Migraine ICYMI